H.C. Wainwright initiates coverage of MBX Biosciences with buy rating and $90 target price
MBX•H.C. Wainwright initiated coverage of MBX Biosciences with a buy rating and a $90 target price.
Related News
Defsec Technologies announces 9-for-1 share consolidation effective Nov. 16
DFSC•
Azul gross debt rises 5.7% quarter-on-quarter to R$ 22.64 billion
AZUL•
Walmart target price raised to $147 from $136 by Deutsche Bank
WMT•
Argus Research raises Cardinal Health target price to $309 from $264
CAH•
Century Therapeutics Q3 net income $23.453 million versus IBES estimate of $24.3 million
IPSC•